Stockscreener 앱 받기
1.07%
전일 마감가:
$24.77
열려 있는:
$24.78
하루 거래량:
26.86M
Relative Volume:
0.56
시가총액:
$139.30B
수익:
$63.83B
순이익/손실:
$10.77B
주가수익비율:
13.03
EPS:
1.8799
순현금흐름:
$12.44B
1주 성능:
-1.39%
1개월 성능:
+3.14%
6개월 성능:
+6.31%
1년 성능:
-15.09%
1일 변동 폭
$24.50
$24.78
1주일 범위
$24.50
$24.93
52주 변동 폭
$20.91
$29.17
화이자 Stock (PFE) Company Profile
명칭
Pfizer Inc
전화
(212) 733-2323
주소
66 HUDSON BOULEVARD EAST, NEW YORK, NY
PFE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
24.50 | 140.83B | 63.83B | 10.77B | 12.44B | 1.8799 |
|
LLY
Lilly Eli Co
|
814.22 | 740.84B | 53.26B | 13.80B | -50.20M | 15.08 |
|
JNJ
Johnson Johnson
|
187.13 | 458.49B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
227.23 | 402.83B | 58.33B | 3.73B | 18.24B | 2.1013 |
|
NVS
Novartis Ag Adr
|
123.73 | 250.00B | 53.40B | 13.68B | 16.89B | 6.8864 |
|
MRK
Merck Co Inc
|
87.07 | 219.80B | 63.43B | 16.42B | 14.72B | 6.4861 |
화이자 Stock (PFE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-22 | 개시 | Cantor Fitzgerald | Neutral |
| 2024-12-10 | 재개 | BofA Securities | Neutral |
| 2024-11-15 | 개시 | Wolfe Research | Underperform |
| 2024-10-25 | 재개 | Citigroup | Neutral |
| 2024-10-17 | 개시 | Bernstein | Mkt Perform |
| 2024-08-07 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | 다운그레이드 | Argus | Buy → Hold |
| 2024-02-23 | 개시 | Guggenheim | Buy |
| 2024-01-04 | 다운그레이드 | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | 재개 | UBS | Neutral |
| 2023-10-16 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-07-17 | 재확인 | JP Morgan | Neutral |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-06-29 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | 개시 | Jefferies | Hold |
| 2023-02-07 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | 다운그레이드 | UBS | Buy → Neutral |
| 2023-01-17 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-12-13 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-11-18 | 개시 | Credit Suisse | Outperform |
| 2022-05-23 | 개시 | SVB Leerink | Mkt Perform |
| 2022-04-06 | 재개 | Morgan Stanley | Equal-Weight |
| 2022-01-05 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2022-01-03 | 재확인 | Bernstein | Mkt Perform |
| 2021-12-20 | 재확인 | Cowen | Outperform |
| 2021-12-17 | 개시 | Goldman | Neutral |
| 2021-12-13 | 업그레이드 | UBS | Neutral → Buy |
| 2021-12-09 | 개시 | Wells Fargo | Overweight |
| 2021-11-19 | 개시 | BMO Capital Markets | Outperform |
| 2021-07-27 | 재개 | Truist | Buy |
| 2021-05-06 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2021-04-07 | 재개 | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | 업그레이드 | DZ Bank | Hold → Buy |
| 2020-12-16 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | 재개 | Goldman | Neutral |
| 2020-11-10 | 재개 | Bernstein | Mkt Perform |
| 2020-10-12 | 다운그레이드 | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | 개시 | Berenberg | Hold |
| 2020-06-16 | 개시 | SVB Leerink | Mkt Perform |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-02-27 | 업그레이드 | Standpoint Research | Hold → Buy |
| 2020-02-06 | 개시 | Mizuho | Buy |
| 2020-01-07 | 개시 | RBC Capital Mkts | Outperform |
| 2019-10-17 | 재개 | BofA/Merrill | Neutral |
| 2019-07-30 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | 재개 | Morgan Stanley | Overweight |
| 2019-02-20 | 재개 | Citigroup | Neutral |
| 2019-01-31 | 업그레이드 | Argus | Hold → Buy |
| 2019-01-31 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | 다운그레이드 | UBS | Buy → Neutral |
| 2018-12-11 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2018-11-01 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
모두보기
화이자 주식(PFE)의 최신 뉴스
Eye Health Supplements Market Is Booming Worldwide 2025-2032 | - openPR.com
Pfizer Whistleblower's Story Unveiled: Becky McClain's "Exposed" Memoir Hits Shelves October 28 - PR Newswire
United States Adult Vaccine Market Research and Company Analysis Report 2025-2033 Featuring GlaxoSmithKline, AstraZeneca, Sanofi Pasteur, Pfizer, and CSL Limited - Yahoo Finance
Will Pfizer Inc. stock benefit from sector rotationDollar Strength & Weekly Market Pulse Updates - Fundação Cultural do Pará
Pfizer’s Latest Clinical Trial: A New Hope for Prostate Cancer Treatment - TipRanks
Pfizer’s Pediatric Migraine Study: A Potential Game-Changer for Rimegepant - TipRanks
Pfizer’s Pediatric Ulcerative Colitis Study: A Potential Game-Changer - TipRanks
Pfizer’s New Study on Ritlecitinib: A Potential Game-Changer for Chronic Urticaria? - TipRanks
Pfizer’s Promising Phase 3 Study on Prostate Cancer Treatment: A Market Game-Changer? - TipRanks
Pfizer’s Pediatric Migraine Study: A Potential Game-Changer in Migraine Treatment - TipRanks
Pfizer’s Phase 3 RSV Vaccine Study: A Potential Game Changer for Pregnant Women - TipRanks
Pfizer and BioNTech’s New Shingles Vaccine Study: A Potential Game Changer - TipRanks
Pfizer’s Ponsegromab Study: A Potential Game-Changer in Pancreatic Cancer Treatment - TipRanks
Pfizer’s Promising Phase 3 Study on Menstrual Migraine Prevention with Rimegepant - TipRanks
Pfizer’s BEATRIX Study: A New Frontier in Maternal and Infant Health - TipRanks
Pfizer and Bristol-Myers Squibb’s Promising Study on Multiple Myeloma Treatment - TipRanks
Pfizer’s Elranatamab Study: A New Chapter in Multiple Myeloma Treatment - TipRanks
Pfizer’s Phase 3 Study on Elranatamab for Multiple Myeloma: A Potential Game-Changer? - TipRanks
Pfizer’s Pediatric Migraine Study: A Potential Game-Changer? - TipRanks
Pfizer’s New Study: A Potential Game-Changer in Prostate Cancer Treatment? - TipRanks
Pfizer’s Promising Migraine Study: A Potential Game-Changer for Adolescents - TipRanks
Pfizer’s New Study on Zavicefta: A Potential Game-Changer in Infection Treatment - TipRanks
Pfizer’s Phase 3 Study on PF-06823859: A Potential Game-Changer for Myositis Treatment - TipRanks
Pfizer’s Latest Clinical Trial: A New Hope for NSCLC Treatment? - TipRanks
Pfizer’s New Study on PF-07934040: A Potential Game-Changer in Cancer Treatment? - TipRanks
Pfizer and Genmab’s Tivdak Study: Ocular Side Effects Under the Microscope - TipRanks
Pfizer’s Promising Trial for Multiple Myeloma: A Potential Game-Changer - TipRanks
Pfizer’s Abrocitinib Study: A Real-World Look at Treating Atopic Dermatitis - TipRanks
Pfizer’s Somatrogon Study: A New Hope for Pediatric Growth Hormone Deficiency - TipRanks
Pfizer’s Latest Clinical Study: Exploring Carbamazepine’s Impact on PF-07248144 - TipRanks
Pfizer’s Promising Phase 1 Study on PF-07799933 for Advanced Tumors - TipRanks
Pfizer’s Promising Phase 3 Study on Ritlecitinib for Severe Alopecia Areata in Children - TipRanks
Pfizer’s Prostate Cancer Study: Long-term Safety and Market Impact - TipRanks
Pfizer’s New Bladder Cancer Study: A Potential Game-Changer? - TipRanks
Pfizer’s Xeljanz XR Study: A Closer Look at Safety and Effectiveness - TipRanks
Pfizer’s Promising Atopic Dermatitis Study: A Potential Game-Changer? - TipRanks
Pfizer’s New Study on PF-07258669: A Potential Game-Changer for Elderly Nutrition - TipRanks
Pfizer’s Observational Study on TCR-MM in Italy: A Closer Look at Treatment Practices - TipRanks
Pfizer’s New Phase 3 Study: A Potential Game-Changer in Breast Cancer Treatment? - TipRanks
Pfizer’s Promising Pediatric Leukemia Study: A Potential Game Changer? - TipRanks
Pfizer’s New Phase 1 Study: A Potential Breakthrough for Kidney Disease Treatment - TipRanks
Pfizer’s New Study on Abrocitinib: A Potential Game-Changer for Atopic Dermatitis - TipRanks
Pfizer’s New Study on PF-07868489: A Potential Game-Changer for Pulmonary Arterial Hypertension? - TipRanks
Pfizer’s Prevenar 20 Study: A Key Step in Korean Market Expansion - TipRanks
Pfizer’s Zavicefta Study: A Strategic Move in the Korean Antibiotic Market - TipRanks
Pfizer’s New Study on Rimegepant: What Investors Need to Know - TipRanks
Pfizer’s New Study on Drug Interactions: What Investors Need to Know - TipRanks
Pfizer’s E Coli Vaccine Study: A Promising Step in Infection Prevention - TipRanks
Pfizer’s Etrasimod Study: A Step Forward in Drug Safety for Breastfeeding Women - TipRanks
Pfizer’s New Study on TUKYSA: What Investors Need to Know - TipRanks
Pfizer’s Phase 3 Study on Ritlecitinib for Vitiligo: A Market Game-Changer? - TipRanks
화이자 (PFE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.76%
자본화:
|
볼륨(24시간):